Equitable Holdings heads into its May 5 earnings report with a notable insider-selling pattern running against a stock that has quietly recovered 10% over the past month.
The insider angle is the standout here. CEO Mark Pearson sold roughly $1.65 million in shares on April 20, adding to a cluster of executive sales that also included the COO and a divisional president on April 15 and April 8. Net insider activity over the past 90 days amounts to over $20 million in net selling. That is not a trivial figure for a stock trading near $41. The pattern does not necessarily signal alarm — much executive selling reflects pre-planned programs — but the concentration of multiple senior names across several dates adds texture heading into the print.
The short-selling picture is far less charged. Short interest has fallen sharply over the past month, down roughly 14% on the week and 11% over 30 days, now representing about 2.2% of the free float. Borrow costs are negligible at 0.47% annualised, and availability is loose — well clear of the tightest levels seen in the past year. The short score has drifted lower through April, from 32 to 30.6, pointing in the same direction. Whatever pressure shorts applied in mid-April, when estimated short positions were closer to 8 million shares, has substantially unwound.
Options positioning has moved in the opposite direction from the broader market's recent defensiveness, and it is a meaningful shift. The put/call ratio has eased to 1.48 — more than a full standard deviation below its 20-day average of 1.80 — suggesting that options traders have become noticeably less bearish than they were through most of April, when the ratio was running above 2.0. That is a cleaner read than the short interest alone.
The analyst community is broadly constructive but trimming. JP Morgan kept its Overweight and nudged its target down a dollar to $57 on April 29. Raymond James upgraded to Strong Buy just last month with a $58 target. The rest of the pack — Mizuho, Wells Fargo, UBS, Barclays — shaved targets in early April, likely in response to macro repricing, while all maintained positive ratings. The mean target of roughly $57 implies about 38% upside to the current $41.49 price, ranking this stock near the top of the universe on analyst return potential. The valuation is undemanding: the forward P/E has compressed to around 5.5x, down over the past month, while the earnings yield runs above 18%.
Institutional ownership tells a constructive story too. BlackRock added nearly 1.4 million shares in Q1 and T. Rowe Price added over 1.1 million; Capital Research and Management built a position by more than 2.6 million shares. Diamond Hill added over 2.3 million in the same period. Against that backdrop, the CEO-led selling looks more like personal liquidity management than a directional call.
Today's print is the first real test of whether the valuation re-rating that began in April — the P/E expanding by over 0.6x in a month — is supported by the underlying numbers, or whether executive caution was better-informed than the recovering price suggested.
See the live data behind this article on ORTEX.
Open EQH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
